That is what happens at the moment in the European Union and those Member States who allow research on that (we always said they could continue) but the patients there also deserve the right to have the safest, best products available, and that is why I tabled an amendment on subsidiarity making it sure again (and that amendment is in the package).
Referents paskaidroja, ka Eiropas Komisijas priekšlikums paredz dalībvalstīm iespēju ieviest izņēmumus un atteikties no noteiktu produktu komercializācijas savā teritorijā: "Praksē tas nozīmēs, ka dažiem produktiem nav pieeja visu dalībvalstu tirgiem."